Transcript Diapositive 1 - Moodle Lille 2

Business model
Martin Dalle – Rémi Delbassez – Claire Dubois – Rémi Fruleux
5th year students
1
History and presentation
A modern story
Decided to found a
joint venture in 1999
2
History and presentation
A modern story
Field of vaccine
Cell line without fetal bovine serum
Currently incorpored in J&J company since 2010
3
History and presentation
A modern story
Field of infectious diseases, especially AIDS
Well known medicines like:
darunavir, etravirine and rilpivirine…
Currently incorpored in J&J company since 2002
4
History and presentation
A modern story
Indirectly shareholder of 7.9 % in
Galapagos
5
History and presentation
A modern story
830 staff
Research sites in 5
countries
HQ in Belgium
Broad pipeline: 30
discovery programs
6
History and presentation
A wide range of drug discovery services
7
History and presentation
Hybrid model
8
9
CRO activities
CRO activities
Neurodegeneration
Inflammation
Rare and neglected diseases
10
11
CRO activities
CRO activities
History
12
Services
CRO activities
Respiratory models
dedicated to Cancer Drug Discovery
13
CRO activities
Argenta had been a contributor to 40 pre-clinical
candidates since it was founded in 2000.
14
15
CRO activities
CRO activities
Combines expertise of
• Chemestry
• Pharmacology
• ADME
• Pharmacokinetics
• toxicology
Inflammation antibacterial
16
Strategic alliances
Alliance business
Typical partnerships
between a biotech and Big
Pharma
17
Strategic alliances
Alliance business
18
Strategic alliances
Alliance business
The best seller of Abbvie: Humira® also indicated in RA
High strategic alliance !
Patent Cliff: 2016
19
Discovery
Pipeline
20
GLPG 0634 JAK 1 inhibitor
Discovery
GLPG0634 biochemical potency
GLPG0634 WBA potency
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases J
Immunol 2013; 191:3568-3577
21
Discovery
JAK inhibitors
22
Preclinical data
Rat collagen-induced arthritis model
Discovery

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases J
Immunol 2013; 191:3568-3577
23
24
Discovery
25
Discovery
26
Discovery
27
Discovery
Discovery
Concentration and JAK inhibition
28
Results PoC and Phase 2a
p≤0.05
p≤0.05
Discovery
p≤0.01
p≤0.05
29
30
Discovery
31
Discovery
Discovery
GLPG 778
32
Discovery
GLPG0974, a selective FFA2
antagonist
33
34
Discovery
Discovery
FFA2 physiology
35
Discovery
Preclinical Data
36
37
Discovery
38
Discovery
Discovery
Preclinical Data
39
40
Discovery
Possible indication for GLPG0974:
41
Financial analysis
2013 revenues
42
Financial analysis
Distribution of shareholders
2011
2013
43
Fluctuation of profitability
€M
Capital increase
5
Financial analysis
0
-5
-10
-15
2007
2008
2009
2010
2011
2012
-20
Extrapolation
2013
-25
-30
-35
Failure of Janssen Deal
44
R&D revenue
€M
80
70
Financial analysis
60
50
40
30
20
10
0
2007
2008
2009
2010
2011
2012
R&D revenue
45
Change of direction
€M
80
Financial analysis
60
40
20
0
2007
2008
2009
2010
2011
2012
-20
-40
-60
-80
-100
Services cost
R&D costs
services revenue
R&D revenue
46
47
Financial analysis
Marketing expenses
€M
3
Financial analysis
2.5
2
1.5
1
0.5
0
2007
2008
2009
2010
2011
juin-12
Extrapolation
2013
48
Intangible assets
€M
Financial analysis
15
10
5
0
2007
2008
2009
2010
2011
2012
Jun-13
49
SWOT
Strategic alliances
High reactivity
First-in-class
Hybrid Model
BioFocus & Argenta
Management with
experience
To become a pharma
Small molecules VS
biologics
New alliances
No product on the market
First-in-class
Venture capital
Patents
Risk of 634’s failure
Many other JAKInhibitors in pipelines
Evolution of R&D
technologies
50
Discussion
To work in this Company?
51